publication date: Oct. 1, 2014


html Gastric.html

Phase III Cyramza Trial Meets OS Primary Endpoint

A global phase III trial of Cyramza (ramucirumab) in combination with paclitaxel in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma met its primary endpoint of median overall survival.

In the trial, known as RAINBOW, the addition of ramucirumab to paclitaxel also met secondary endpoints of progression-free survival and objective response rate. The global, double-blinded study enrolled a total of 665 patients refractory to or progressive after initial platinum- and fluoropyrimidine-containing chemotherapy.

Patients randomized to receive ramucirumab plus paclitaxel had a median survival benefit of 9.6 months, compared to 7.4 months for patients who received paclitaxel and placebo (stratified HR 0.807 [95% CI, 0.678-0.962; p=0.0169]).

Treatment with ramucirumab plus paclitaxel significantly reduced the risk of disease progression or death by 37 percent, with a 52 percent increase in median progression-free survival compared with placebo plus paclitaxel (4.4 vs. 2.9 months; stratified HR 0.635 [95% CI, 0.536-0.752; p < 0.0001]).

There was a statistically significant increase in objective response rate, from 16 to 28 percent, with the addition of ramucirumab (p=0.0001).

RAINBOW is the largest trial in second-line gastric cancer to date and the first phase III study to demonstrate a survival benefit with a biologic used in combination with chemotherapy in this setting, according to the drug’s sponsor, Eli Lilly and Company. Data were published in The Lancet Oncology, after being first presented at the Gastrointestinal Cancers Symposium in January.

Grade 3 or higher adverse events occurred at a higher rate and for more than 10 percent of patients on the ramucirumab-plus-paclitaxel arm: neutropenia; leukopenia; hypertension; and fatigue. Febrile neutropenia incidence … Continue reading CCL Sept – Gastric Cancer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.